Simultaneous hepatitis B, C and HIV screening with rapid tests and FibroScan for people who use drugs and other vulnerable adults outside hospitals
Official title: Acceptability and Feasibility of Simultaneous Screening for Viral Hepatitis B, C and HIV Among Drug Users and Vulnerable Populations, in Non-conventional Structures "Outside the Walls" by Dual Screening Method RTDs and FibroScan®
Run by University Hospital, Limoges · NCT06904820 · Data updated 2026-11-12
This project will try offering rapid blood tests and on-site FibroScan to find hepatitis B, C and HIV and quickly link people who use drugs and other vulnerable adults to care.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 2300 (estimated) |
| Sponsor | University Hospital, Limoges Academic / other |
| Locations | 1 site (Limoges) |
| Status | Recruiting |
| Started | June 5, 2025 |
| Main results expected | June 5, 2035 |
| Study ends | June 5, 2035 |
| Registry record updated | August 14, 2025 |
| Trial ID | NCT06904820 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (18+) who use drugs or belong to vulnerable populations and who attend designated non-traditional care sites or are referred by professionals, and who do not oppose participation in research.
✕Probably not a fit
People under 18, those who refuse participation, or individuals already engaged in regular hepatitis care or already cured are unlikely to gain added benefit from this program.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The SCANVIR approach brings simultaneous rapid testing for hepatitis B, C and HIV plus on-site liver stiffness measurement (FibroScan) to non-traditional care settings such as addiction centers and harm-reduction sites. It uses dedicated screening days to test, start treatment when possible, and follow up people who inject drugs (PWIDs) and other vulnerable groups who often miss usual care pathways. The project is observational and focuses on feasibility, acceptability and reproducibility of this ‘‘test, treat and cure’’ model initially implemented across several French departments. Enrollment is limited to adults (18+) attending designated outside-the-walls sites or referred by care professionals who do not object to research.
Why it matters
Potential benefit: If successful, this approach could increase diagnosis and rapid treatment initiation for hepatitis C and related infections in hard-to-reach populations, reducing future liver disease and transmission.
How similar studies have gone: Community-based test-and-treat programs for hepatitis C among PWIDs have shown promising improvements in diagnosis and treatment uptake, so this approach builds on prior successful models.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult 18 and over * Patient frequenting an unconventional structure "outside the walls" or referred by a professional in the care sector * Patient not opposed to research Exclusion Criteria: * Age under 18 * Patient opposed to research
Where it's running
-
Limoges University Hospital
Limoges, France Recruiting
Study contacts
- Principal investigator: marilyne DEBETTE-GRATIEN, MD — University Hospital, Limoges
- Study coordinator: Marilyne DEBETTE-GRATIEN, MD
- Email: marilyne.gratien@chu-limoges.fr
- Phone: +33555056604
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Comparing Tenofovir Alafenamide and Entecavir for Chronic Hepatitis B Treatment
This study is testing whether a newer hepatitis B medication called tenofovir alafenamide works as well as an older one called entecavir, while also being safer for the kidneys.
-
Creating biological models to study liver diseases and tumors
This study is trying to create new models to better understand liver diseases and tumors so that we can find better treatments for people suffering from these conditions.
-
Assessing liver stiffness measurements in chronic viral hepatitis patients
This study is testing how reliable and consistent liver stiffness measurements are in people with chronic viral hepatitis using a special ultrasound technique.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.